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Synthesis of 2'-aminoalkyl-1-benzylisoquinoline derivatives and 
medium sized ring analogues with mu opiod receptor binding 
activities. 
 
Uta Mbere-Nguyen, Alison T. Ung* and Stephen G. Pyne* 
School of Chemistry, University of Wollongong, Wollongong, NSW, 2522, Australia 
 
spyne@uow.edu.au 
 
Abstract:  
 
Novel 2'-aminoalkyl-1-benzylisoquinoline compounds and medium size ring 
analogues have been prepared using reductive alkylation methods. Four of these 
analogues were tested for biological activity across 48 different CNS receptors and 
were showed to have binding activities at the mu opiod receptor. 
1. Introduction. 
The 1-benzylisoquinolines alkaloids constitute a group of natural products of 
diverse structure that are widely present in many plants and mammalian species.1,2 
About 2500 1-benzylisoquinoline alkaloids have been identified and shown to have a 
wide range of biological activities including anticancer,2 antimalarial,3 anti-HIV,4 
antiplatelet and vaso-relaxant.5,6 Several natural and synthetic benzylisoquinoline 
derivatives have also displayed affinities for dopamine and seretonin receptors, which 
are important neurotransmiters in the central nervous system (CNS).7 Examples of 
some of these 1-benzylisoquinoline derivatives are shown in Figure 1. Compounds 
with these biological activities have potential application in the treatment of numerous 
physiological and behavioural disorders such as schizophrenia, anxiety, Parkinson’s 
and Huntington‘s disease.7  
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Figure 1. 1-Benzylisoquinoline derivatives that were found to be dopaminergic 
ligands in the micromolar range.7 
 
There are also an emerging class of CNS active compounds that contain an 
amino group appended to a heterocyclic base structure (Figure 2), for example the 
high affinity 5HT1A receptor agonist repinotan 3
8 and the 5HT7 active molecule SB-
691673 4.9 Medium sized ring CNS active compounds are known, including the D1-
antagonist LE 300 510 and the partial D1/D5 agonist SCH 39166 6.10-12 
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Figure 2. The structures of known CNS active compounds.8-12 
In our continuing project concerned with the discovery of new bioactive 
benzylisoquinoline derivatives,13-15 the 2'-aminoalkyl-1-benzylisoquinoline compound 
7 and the medium side ring analogues 8 were of interest. We report here our attempts 
to synthesise these compounds and the biological activities of four of these analogues 
on 48 different CNS receptors.  
 
Figure 3. The targeted 1-benzylisoquinoline derivatives containing 2’-aminoalkyl   
substituents (7) and the medium sized ring targets (8). 
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2. Results and Discussion. 
 
 
 
Scheme 1. Attempted synthesis of 11 using lithium morpholinamide and the 2'-
vinyllaudanosine derivative 10. 
 
With the aim of preparing 2'-aminoethyl-1-benzylisoquinoline derivatives, we 
first examined the method reported by Seijas et al. towards the preparation of -
phenylethylamines derivatives by addition of primary and secondary lithium amides 
to styrene.16 The racemic 2'-vinyllaudanosine derivative 10 was prepared from the 
known N-TFA derivative 914,15 in 75% overall yield. Morpholine was treated with n-
butyl lithium and the resulting solution of lithium morpholinamide in THF was added 
to compound 10 at 0 oC. The mixture was left at 0 oC for 18 h. 1H NMR analysis only 
showed unreacted starting material 10 and no morpholine ethylene signals were 
observed. This suggests that the vinyl group of 10 was too electron rich to react with 
the lithium morpholinamide nucleophile. Therefore an alternative synthesis of the 2'-
aminoethyl-1-benzylisoquinoline and 2'-aminomethyl-1-benzylisoquinoline 
derivatives was examined using a reductive amination method (Scheme 2). Here the 
racemic aldehydes 15 and 16 were prepared in good yields from the known alkenes 9 
and 12,14-15 respectively, using the 2 step sequence of dihydroxylation, followed by 
oxidative cleavage.17,18 
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Scheme 2. Preparation of the aldehydes 15 and 16 via oxidative cleavage of the diols 
13 and 14, respectively. 
 
The aldehydes 15 and 16 were subjected to reductive amination reactions with several 
amines to give the corresponding aminated products in moderate to good yields 
(Scheme 3, Table 1). 
 
 Scheme 3 
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Table 1 Synthesis of 2'-aminomethyl-1-benzylisoquinoline analogues by 
reductive amination, followed by N-TFA cleavage and N-methylation. 
 
The final 2'-aminoalkyl-1-benzylisoquinoline derivatives required for biological 
testing were obtained by basic hydrolysis of the TFA group of 17-23, followed by 
reductive N-methylation using a literature procedure.19 The final products 11 and 24-
29 were obtained in moderate to high yields (Table 1). 
 Overall, the above reductive amination procedure was an effective method 
used to synthesise a small library of seven 2'-aminoalkyl-1-benzylisoquinoline 
derivatives which represent a new class of 1-benzylisoquinolines.  
 
The synthesis of the medium sized ring 1-benzylisoquinoline derivative 35 
was attempted utilising the reductive amination method developed in Scheme 3 to 
facilitate the intramolecular coupling between the aldehyde and the amine group of 32 
to provide the medium ring compound 35 (Scheme 4). The synthesis started with the 
reductive amination reaction between the aldehyde 15 and commercially available 
aminoacetaldehyde diethylacetal, followed by basic hydrolysis of the N-TFA group to 
afford the desired product 31 in 82% overall yield. Conversion of the diethoxyl acetal 
group of the bis-amine 31 into the corresponding aldehyde 32 was attempted using 
TsOH/CH3OH/H2O at rt to reflux temperature, however no product was obtained. 
Alternatively, the amine 31 was heated in a solution of 10% aqueous HCl/MeOH at 
Entry Aldehyde Amine Reductive amination N-TFA cleavage and N-
methylation 
  R1 R2 product yield product yield 
1 15 -CH2CH2-O-CH2CH2- 17 60% 24 73% 
2 15 -CH2CH2CH2CH2- 18 74% 25 71% 
3 15 CH2CH3 CH2CH3 19 75% 26 58% 
4 15 H CH(CH3)2 20 64% 27 (R
1 = 
CH3) 
59% 
5 16 -CH2CH2-O-CH2CH2- 21 64% 11 85% 
6 16 -CH2CH2CH2CH2- 22 74% 28 69% 
7 16 CH2CH3 CH2CH3 23 68% 29 69% 
 7
110 oC to afford only the corresponding dimethoxyl acetyl compound 33 which arose 
from exchange of the diethoxyl acetal group with the solvent methanol. Further 
heating of compound 33 in 10% aqueous HCl/MeOH afforded a crude product, which 
when 1H NMR analysis was performed, showed that the dimethoxy signal at  3.36 (s, 
6H, CH(OCH3)2) had disappeared, however, the expected aldehyde signal in the  9-
10 region was not observed. ESIMS analysis showed a MH+ signal at m/z 415.0 which 
would correspond to the hemiacetal 34. The crude compound was subjected to the 
reductive amination conditions with NaCNBH3, however no identifiable products 
were obtained.  
 8
 
 
Scheme 4  
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Alternatively (Scheme 5), the aldehydes 15 and 16 were reductively coupled 
with methylamine to afford the corresponding benzylisoquinolines 36 and 37 in 71% 
and 79% yield, respectively. The amines 36 and 37 subsequently underwent N-
acylation with chloroacetyl chloride to give the corresponding -chloroacetamides 38 
and 39 in good yields (72-80%). Hydrolysis of the N-TFA group of 38 and 39 
exposed the free amino groups for an intramolecular SN2 displacement of the chloride 
under basic conditions with triethylamine to provide the desired medium ring 
compounds 40 and 41 in moderate yields (46-57% over 2 steps). The 9-membered 
ring 40 was subjected to carbonyl reduction using lithium aluminium hydride to 
afford the corresponding cyclic amino compound 42 in 81% yield. Analysis of the 1H 
NMR spectrum of 42 revealed the newly formed methylene proton resonances for 
H2″ at  2.79 (m, 1H), 2.57 (m, 1H) and for H3″ at  3.10 (m, 1H), 2.79 (m, 1H). 
These newly observed methylene proton signals confirmed the succesful amide 
reduction to the amine 42. The benzylic protons of 42 were observed more 
prominently at  4.49 (d, 1H, J 12.5 Hz, H1″) and 3.42 (d, 1H, J 12.5 Hz, H1″). 
◦ 
 10
 
Scheme 5 
3. In vitro CNS Receptor Binding Studies. 
The in vitro testing was conducted at Cerep Corporation in France. Four 2'-
aminoalkyl-1-benzylisoquinoline derivatives 11, 25, 26 and 27 were tested for 
biological activities on 48 different CNS receptors.20 The activities were expressed as 
% inhibition of control specific binding (Table 2), which is the measure of the direct 
inhibition activity of the tested drug exerted on the controlled ligand. Therefore the 
drug is considered active when the % inhibition of control specific binding is high at 
the CNS receptor type tested.  
 11
The CNS binding activities of the four derivatives 11, 25-27 are shown in 
Table 2. All four compounds showed binding activities at the mu ( opiod receptor 
(MOP), with compound 11 having the highest mu receptor activity with 46% 
inhibition of the control (DAMGO) specific binding at 1 M concentration.  
Compound 26 was tested at 10 M concentration and was shown to have binding 
activities against several receptors, most prominently at the muand kappa opiod 
(KOP) receptors, with inhibition activities of 52% and 40%, respectively. The IC50 of 
these compounds are yet to be determined, but that of compound 11 and 27 would  be 
estimated to be in the low micromolar range activities against the mureceptor.  
 
Table 2 
 
In vitro CNS receptor binding activities of compounds 11 and 25-27. Across the 48 CNS receptors, 
only the receptors with 25 % or more of inhibition activities are illustrated below. 
 
Assay Reference compounds % Inhibition of control specific binding at 1 M 
Reference 
compound 
IC50 
(nM) 
Compound 
11 
Compound 
25 
Compound 
26a 
Compound 
27 
(h) 
(MOP) 
DAMGO 1.2 46 25 52 35 
KOP) U 50488 1.2 - - 40 - 
V1a (h) [d(CH2)51,T
yr(Me)2]-
AVP 
1.8 - - 37 - 
1 (non 
selective) 
prazosin 0.30 - - 25 - 
Na+ 
channel 
veratridine 4650 - - 25 - 
 
a Testing was conducted at 10 M concentration. 
The symbol – indicate binding inhibition of less than 25 %. 
 
The muopiod receptor is one major class of opiod receptors which has been targeted 
for its analgesic properties.21 Opiod agonists such as morphine exert their activities 
mainly at the mu opiod receptor and have been widely used in pain therapy.21 Chronic 
morphine therapy, however, can produce unwanted side effects such as tolerance, 
 12
respiratory suppression and constipation.21 Muopiod antagonists are commonly used 
as a rescue medication to reverse these side effects as well as combating alcohol and 
narcotic addiction.22-23 Muopiod antagonists also have potential applications in the 
treatment of obesity, psychosis and Parkinson’s disease.22 Therefore, depending on 
their agonist or anatagonist properties, compounds  11 and 25-27 and their analogues 
could be used in pain treatment therapy, or for the treatment of narcotic addictions as 
well as obesity, psychosis and Parkinson’s disease.  
In conclusion, seven novel 2'-aminoalkyl-1-benzylisoquinoline analogues and 
three medium sized ring 1-benzylisoquinoline analogues were successfully 
synthesised. Four analogues 11, 25, 26 and 27 showed moderate to good inhibition of 
control specific binding activities at 1-10 M concentrations against the mureceptor. 
Unfortunately, compounds 24, 28-29 and 40-42 were unable to be tested.  
4. Experimental  
Petrol refers to the fraction of petroleum spirit with a boiling point of 40-60C.  All 
1H NMR spectra were performed at 300 MHz and all 13C NMR and DEPT spectra at 
75 MHz in CDCl3 solution, unless otherwise noted. All spectra were referenced to 
CDCl3 (
1H  7.26 ppm and 13C NMR  77.00 ppm). 1H NMR assignments were 
achieved with the aid of gCOSY, and in some cases NOESY and TOCSY 
experiments. 13C NMR assignments were based on DEPT, gHSQC and gHMBC 
experiments. All compounds were homogeneous by TLC analysis and judged to be of 
>95% purity based upon 1H NMR analysis. Compound numbering of 1-
benzylisoquinoline derivatives is based on that of compounds 11 and 24. Compound 
numbering of the medium ring benzylisoquinoline derivatives is based on that of 
compounds 40 and 41. 
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 (RS) 1-(2'-Ethenyl-4',5'-dimethoxyphenyl)methyl-1,2,3,4-tetrahydro-6,7-
dimethoxy-2-methylisoquinoline  (10). 
 
To a solution of the 2'-vinyllaudanosine derivative 9 (227 mg, 0.487 mmol) in a 
mixture of CH3OH (20 mL) and H2O (3 mL) at rt was added K2CO3 (339 mg, 2.44 
mmol). The reaction mixture was stirred for 18 h at rt.  The CH3OH was evaporated 
and the residue was dissolved in CH3CN (10 mL). 38% Formaldehyde (8 mL) was 
added to the solution, followed by NaCNBH3 (41 mg, 0.633 mmol). The reaction was 
stirred for 20 min at rt and the pH was adjusted to ~6 using glacial acetic acid. The 
reaction mixture was stirred for 18 h at rt. The solvent was evaporated and the residue 
was dissolved in CH2Cl2 and washed with 1M aqueous NaOH, H2O (2 x) and dried 
(K2CO3) to give an oil. The oil was purified by column chromatography 
(CH3OH/EtOAc/NH3 (3:7:0.1)) to give 10 (140 mg, 75% overall) as a yellow oil. Rf. 
0.25 (CH3OH/EtOAc (1:1)). 
1H NMR:  6.97 (s, 1H, H3'), 6.73 (dd, 1H, J 17.4, 10.8 
Hz, H1''), 6.54 (s, 1H, H5), 6.39 (s, 1H, H6'), 5.72 (s, 1H, H8), 5.45 (dd, 1H, J 17.4, 
1.2 Hz, H2''(E)), 5.11 (dd, 1H, J 10.8, 1.2 Hz, H2''(Z)), 3.86 (s, 3H, OCH3-4'), 3.80 (s, 
3H, OCH3-6), 3.72 (s, 3H, OCH3-7), 3.68-3.62 (m, 1H, H1), 3.43 (s, 3H, OCH3-5’), 
3.28-3.25 (m, 1H, H3), 3.24 (dd, 1H, J 13.5, 4.8 Hz, H7'),  2.94-2.78 (m, 2H, H3, H4), 
2.76 (dd, 1H, J 13.5, 9.0 Hz, H7'), 2.64-2.57 (m, 1H, H4), 2.54 (s, 3H, NCH3). MS 
 14
(ESI+): m/z 384 (MH+, 20%). HRMS (ESI+): calcd for C23H30NO4, 384.2175 (MH
+), 
found 384.2180. 
 
Attempted synthesis of (RS) 1,2,3,4-tetrahydro-6,7-dimethoxy-1-(4',5'-
dimethoxy-2'-(2''-morpholinoethyl)phenyl)methyl-2-methylisoquinoline (11). 
 
To a solution of 10 (139.5 mg, 0.364 mmol) in dry THF (4 mL) was added a solution 
of lithium morpholinamide, prepared by the addition of 2.5M nBuLi in hexane (0.2 
mL, 0.5 mmol) to a solution of morpholine (79.3 mg, 0.91 mmol, 0.1 mL) in dry THF 
(1 mL) at 0oC. The reaction mixture was kept at 0oC for 18 h. The reaction mixture as 
quenched with CH3OH and the solvent was evaporated. The residue was purified by 
column chromatography to retrieve only a quantitative amount of starting material 10. 
General method for dihydroxylation.17,18  
 To a solution of the olefin in acetone was added potassium osmate dihydrate 
(K2OsO4.2H2O), followed by N-methylmorpholine N-oxide (NMO). H2O was 
subsequently added and the mixture was stirred at rt for 18 h. Sodium sulfite 
(Na2SO3) (ca. 10 equiv.) was added and stirred for 30 min before the acetone was 
evaporated. Water was added and the mixture was extracted with CH2Cl2. The 
combined CH2Cl2 extracts were washed with brine, dried (MgSO4), and evaporated to 
give an oil. The oil was purified by column chromatography (EtOAc) to afford the 
desired product.  
 
(1RS, 1''RS) and (1RS, 1''SR) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-1-[2'-(1'',2''-
dihydroxyethyl)-4',5'-dimethoxypheny]methyl-6,7-dimethoxyisoquinoline (13). 
 
A solution of the olefin 9 (135 mg, 0.290 mmol) in acetone (3 mL) was treated as 
described above in the general dihydroxylation reaction procedure using 
K2OsO4.2H2O (6 mg, 0.015 mmol), NMO (72 mg, 0.609 mmol) and H2O (1 mL). 
Purification by column chromatography gave the diol 13 (119 mg, 82%) as a light 
yellow oil. The diol 13 was obtained as a 4:1 mixture of diastereomers. Rf. 0.39 
(EtOAc). 1H NMR of the major diastereomer:  6.99 (s, 1H, H3'), 6.61 (s, 1H, H5), 
6.31 (s, 1H, H6'), 6.08 (s, 1H, H8), 5.48 (dd, 1H, J 8.2, 5.8 Hz, H1), 5.08 (dd, 1H, J 
8.1, 4.2 Hz, H1''), 3.94 (dt, 1H, J 13.5, 3.6 Hz, H3), 3.85 (s, 3H, OCH3-7), 3.84 (s, 3H, 
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OCH3-5'), 3.78 (dt, 1H, J 12.6, 4.8 Hz, H3), 3.69 (s, 3H, OCH3-4'), 3.68-3.60 (m, 2H, 
2xH2''), 3.57 (s, 3H, OCH3-6), 3.17 (dd, 1H, J 13.5, 5.8 Hz, H7'), 3.03 (dd, 1H, J 
13.5, 8.2 Hz, H7'), 2.98-2.93 (m, 1H, H4), 2.84-2.76 (m, 1H, H4). 1H NMR of the 
minor diastereomer (in part):  6.95 (s, 1H, H3'), 6.49 (s, 1H, H5), 6.23 (s, 1H, H6'), 
5.59 (t, 1H, J 7.5 Hz, H1), 4.94 (dd, 1H, J 8.1, 4.2 Hz, H1''), 3.77 (s, 3H, OCH3-7), 
3.73-3.71 (m, 2H, 2H2''), 3.68 (s, 3H, OCH3-4'), 3.28-3.23 (m, 1H, H7').
13C NMR of 
the major diastereomer:  156.3 (q, J 36.1 Hz, COCF3), 148.1 (C5', C7), 147.6 (C4'), 
147.0 (C6), 131.8 (C1'), 126.2 (C2'), 125.9 (C4a), 124.6 (C8a), 118.2 (q, J 285.1, 
COCF3), 114.2 (CH-6'), 111.4 (CH-8), 110.8 (CH-5), 109.6 (CH-3'), 70.7 (CH-1''), 
67.3 (CH2-2''), 55.7 (4 x OCH3), 55.5 (CH-1), 40.6 (CH2-3), 38.0 (CH2-7'), 28.2 (CH2-
4). 13C NMR of the minor diastereomer (in part):  132.1 (C1'), 126.1 (C2'), 124.4 
(C8a), 114.4 (CH-6'), 110.2 (CH-5’), 109.5 (CH-3'), 67.5 (CH2-2''), 28.3 (CH2-4). MS 
(EI+): m/z 499 (M+, 20 %). HRMS (ESI+): calcd for C24H28F3NNaO7, 522.1716 
(M+Na+), found 522.1724. 
 
(1RS, 2''RS) and (R,S) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-1-[2'-(2'',3'''-
dihydroxypropyl)-4',5'-dimethoxyphenyl]methyl-6,7-dimethoxyisoquinoline (14). 
 
A solution of the olefin 12 (120 mg, 0.255 mmol) in acetone (7 mL) was treated as 
described above in the general dihydroxylation reaction procedure using 
K2OsO4.2H2O (6 mg, 0.015 mmol), followed by NMO (63 mg, 0.537 mmol) and H2O 
(1 mL) except the reaction mixture stirred for 5 h at rt. The crude oil was purified by 
column chromatography (EtOAc) to give the diol 14 (130 mg, 99%) as clear oil. The 
diol 14 was obtained as a 60:40 mixture of diastereomers. Rf. 0.38 (EtOAc). 
1H NMR 
of the major diastereomer:  6.71 (s, 1H, H3'), 6.61 (s, 1H, H5), 6.39 (s, 1H, H6'), 
6.27 (s, 1H, H8), 5.47 (dd, 1H, J 5.4, 3.3 Hz, H1), 4.02 (dt, 1H, J 8.1, 3.0 Hz, H3), 
3.97-3.91 (m, 1H, H2''), 3.84 (s, 3H, OCH3-7), 3.83 (s, 3H, OCH3-5'), 3.81-3.78 (m, 
1H, H3''), 3.75-3.70 (m, 1H, H3), 3.69 (s, 3H, OCH3-4'), 3.58-3.54 (m, 1H, H3''), 3.52 
(s, 3H, OCH3-6), 3.13 (dd, 1H, J 8.1, 3.3 Hz, H7'),  3.02 (dd, 1H, J 8.1, 5.4 Hz, H7'), 
2.94-2.89 (m, 1H, H1''), 2.88-2.85 (m, 1H, H4), 2.83-2.79 (m, 1H, H4), 2.68-2.62 (m, 
1H, H1''). 1H NMR of the minor diastereomer (in part):  6.70 (s, 1H, H3'), 6.44 (s, 
1H, H6'), 6.01 (s, 1H, H8), 5.59 (dd, 1H, J 5.4, 3.3 Hz, H1), 3.88-3.84 (m, 1H, H2''), 
3.74 (s, 3H, OCH3-4'), 3.66 (s, 3H, OCH3-6), 3.15 (dd, 1H, J 8.1, 3.3 Hz, H7'), 3.03 
(dd, 1H, J 8.1, 5.4 Hz, H7'), 2.97-2.94 (m, 1H, H1''), 2.75-2.71 (m, 1H, H1''). 13C 
 16
NMR of the major diastereomer: (signals for COCF3 and COCF3 were not observed), 
 148.3 (C7), 148.2 (C5’), 147.5 (C6), 147.3 (C4'), 129.3 (C1'), 127.7 (C2'), 126.2 
(C4a), 124.6 (C8a), 114.5 (CH-6'), 113.3 (CH-3'), 111.0 (CH-8, CH-5), 73.1 (CH-2''), 
66.2 (CH2-3''), 55.0 (4 x OCH3), 55.7 (CH-1), 40.8 (CH2-3), 38.6 (CH2-7'), 35.7 (CH2-
1''), 28.5 (CH2-4). 
13C NMR of the minor diastereomer (in part):  148.3 (C7), 147.3 
(C6), 148.0 (C5'), 147.1 (C4'), 129.0 (C1'), 127.9 (C2'), 126.6 (C4a), 124.8 (C8a), 
114.0 (CH-6'), 113.1 (CH-3'), 110.9 (CH-5), 110.4 (CH-8), 72.9 (CH-2''), 66.0 (CH2-
3''), 55.6 (CH-1), 40.4 (CH2-3),  38.5 (CH2-7'), 36.0 (CH2-1''), 28.6 (CH2-4). MS 
(EI+): m/z 513 (M+, 20%). HRMS (ESI+): calcd for C25H31F3NO7, 514.2053 (MH
+), 
found 514.2064. 
General method for oxidative cleavage of diols. 
To a warm solution (ca 40 oC) of NaIO4 in H2O was added silica gel with 
vigorous stirring. The powder was cooled and a solution of the diol in CH2Cl2 was 
added. The mixture was stirred vigorously for 1 h at rt. The CH2Cl2 layer was 
collected by pipetting and the silica was washed several times with CH2Cl2. The 
combined CH2Cl2 washings were evaporated to give pure aldehydes without the need 
for further purification. 
 
(RS) 1-(2'-Formyl-4',5'-dimethoxyphenyl)methyl-2-trifluoroacetyl-1,2,3,4-
tetrahydro-6,7-dimethoxyisoquinoline (15) 
Silica gel coated with NaIO4 was prepared as above using NaIO4 (827 mg, 3.89 
mmol), H2O (2 mL) and silica gel (1.7 g). To this powder was added a solution of the 
vicinal diol 14 (167 mg, 0.335 mmol) in CH2Cl2 (3 mL) which was treated as 
described above in the general oxidative cleavage reaction procedure to afford the 
pure aldehyde 15 (144 mg, 92%) as a white solid. Rf. 0.80 (EtOAc). m.p. 154-158
0C. 
1H NMR:  9.90 (bs, 1H, CHO), 7.28 (s, 1H, H3'), 6.74 (s, 1H, H5), 6.59 (s, 2H, H6', 
H8), 5.64 (dd, 1H, J 8.7, 5.7 Hz, H1), 3.92 (s, 3H, OCH3-7), 3.88 (s, 3H, OCH3-5'), 
3.84 (s, 3H, OCH3-4'), 3.79 (s, 3H, OCH3-6), 3.71-3.54 (m, 3H, 2xH3, H7'), 3.15 (dd, 
1H, J 13.5, 8.1 Hz, H7'), 2.94-2.88 (m, 1H, H4), 2.86-2.70 (m, 1H, H4). 13C NMR: 
(signals for COCF3 and COCF3 were not observed),  190.8 (CHO), 153.0 (C4'), 148.3 
(C6), 148.0 (C5'), 147.8 (C7), 134.1 (C2’), 127.6 (C4a), 126.5 (C1'), 124.7 (C8a), 
114.6 (CH-6'), 113.9 (CH-3’), 110.9 (CH-8), 110.3 (CH-5), 56.0 (OCH3-7, OCH3-5'), 
55.9 (OCH3-4', OCH3-6), 55.1 (CH-1), 40.3 (CH2-3), 37.7  (CH2-7’), 28.6 (CH2-4). 
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MS (EI+): m/z 467 (M+, 10%). HRMS (ESI+): calcd for C23H25F3NO6, 468.1634 
(MH+), found 468.1642. 
 
(RS) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-
(2''-oxoethyl)phenyl]methylisoquinoline (16). 
 
Silica gel coated with NaIO4 was prepared as above using NaIO4 (676 mg, 3.18 
mmol), H2O (2 mL) and silica gel (1.7 g). To this solution was added a solution of 
diol 14 (134 mg, 0.265 mmol) in CH2Cl2 (3 ml) which was reacted as described above 
in the general oxidative cleavage reaction procedure to give the pure aldehyde 16 (127 
mg, 99%) as a clear oil. Compound 16 was a 95:5 mixture of rotamers. Rf. 0.88 
(EtOAc). 1H NMR of the major rotamer:  9.61 (t, 1H, J 2.1 Hz, CHO), 6.60 (s, 2H, 
H3', H5), 6.50 (s, 1H, H6'), 6.02 (s, 1H, H8), 5.33 (dd, 1H, J 8.7, 5.4 Hz, H1), 3.90 
(dt, 1H, J 12.6, 4.5 Hz, H3), 3.86 (s, 6H, OCH3-7, OCH3-5'), 3.74 (s, 3H, OCH3-4'), 
3.67 (dd, 1H, J 8.4, 3.6 Hz, H3), 3.55 (s, 3H, OCH3-6), 3.55-3.47 (m, 2H, 2xH1''), 
3.07 (dd, 1H, J 13.5, 5.4 Hz, H7'), 2.91 (dd, 1H, J 13.5, 8.9 Hz, H7'), 2.89-2.85 (m, 
1H, H4), 2.83-2.78 (m, 1H, H4). 1H NMR of the minor rotamer (in part):  9.43 (bs, 
CHO), 5.87 (s, 1H, H8).13C NMR of the major rotamer:  199.6 (CHO), 156.1 (q, J 
35.8 Hz, COCF3), 148.3 (C4’), 148.2 (C6), 148.2 (C5'), 147.2 (C7), 128.4 (C2'), 125.9 
(C4a), 124.9 (C1'), 123.4 (C8a), 116.5 (q, J 286.4 Hz, COCF3), 114.5 (CH-6'), 113.9 
(CH-3'), 110.9 (CH-8), 110.8 (CH-5), 56.0 (OCH3-7), 55.9 (OCH3-5', OCH3-4’), 55.7 
(OCH3-6), 55.6 (CH-1), 47.8 (CH2-1''), 40.8 (CH2-3), 38.5  (CH2-7'), 28.6 (CH2-4).
13C 
NMR of the minor rotamer (in part):  199.0 (CHO), 40.9 (CH2-3), 55.4 (CH-1), 47.9 
(CH2-1'').
 MS (EI+): m/z 481 (M+, 10%). HRMS (ESI+): calcd for C24H27F3NO6, 
482.1790 (MH+), found 482.1812. 
General method of reductive amination. 
 To a solution of the aldehyde and the amine in CH3CN was added NaCNBH3. 
The reaction was stirred at RT for 20 min before glacial acetic acid was added to 
adjust the pH to ~ 6. The resulting solution was stirred for 18 h at RT. The CH3CN 
was evaporated and the residue was dissolved in CH2Cl2. The solution was washed 
subsequently with H2O (3 x), sat. Na2CO3, brine and dried (MgSO4) to give an oil. 
The oil was purified by column chromatography to afford the pure product. 
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(RS) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-
(morpholino)methylphenyl]methylisoquinoline (17). 
 
A mixture of the aldehyde 22 (58 mg, 0.125 mmol), morpholine (0.10 mL, 1.16 
mmol), CH3CN (15 mL) and NaCNBH3 (10 mg, 0.162 mmol) was treated as 
described above in the general reductive amination reaction procedure to give an oil. 
The oil was purified by column chromatography (EtOAc) to afford 28 (40 mg, 60%) 
as a clear oil. Compound 28 was a 95:5 mixture of rotamers. Rf. 0.38 (EtOAc). 
1H 
NMR of the major rotamer:  6.73 (s, 1H, H3'), 6.59 (s, 1H, H5), 6.47 (s, 1H, H6'), 
6.24 (s, 1H, H8), 5.78 (t, 1H, J 7.2 Hz, H1), 4.04-3.95 (m, 1H, H3), 3.83 (s, 6H, 
OCH3-7, OCH3-5'), 3.75 (dt, 1H, J 7.8, 6.7 Hz, H3), 3.74 (s, 3H, OCH3-4'), 3.65 (t, 
4H, J 4.8 Hz, 2xH3''', 2xH4'''), 3.61 (s, 3H, OCH3-6), 3.41 (d, 1H, J 12.9 Hz, H1''), 
3.22 (dd, 1H, J 13.5, 7.2 Hz, H7'), 3.19 (d, 1H, J 12.9 Hz, H1''), 3.08 (dd, 1H, J 13.5, 
7.2 Hz, H7'), 3.00-2.90 (m, 1H, H4), 2.81-2.73 (m, 1H,  H4), 2.44-2.39 (m, 4H, 
2xH2'', 2xH5'''). 1H NMR of the minor rotamer (in part):  6.71 (s, 1H, H3’), 6.50 (s, 
1H, H6’), 5.96 (s, 1H, H8). 13C NMR of the major rotamer: (signals for COCF3 and 
COCF3 were not observed),  148.2 (C4'), 147.9 (C6), 147.4 (C5', C7), 128.9 (C2'), 
128.7 (C8a), 127.2 (C1'), 124.8 (C4a), 114.2 (CH-3'), 114.1 (CH-6'), 111.0 (CH-5), 
110.4 (CH-8), 67.0 (CH2-3''', CH2-4''), 61.4 (CH2-2''', CH2-5'''), 55.9 (OCH3-7, OCH3-
5'), 55.8 (OCH3-4'), 55.7 (OCH3-6), 55.0 (CH-1), 53.7 (CH2-1''), 40.1 (CH2-3), 37.9 
(CH2-7'), 28.7 (CH2-4). MS (EI
+): m/z 538 (M+, 30%). HRMS (ESI+): calcd for 
C27H34F3N2O6, 539.2369 (MH
+), found 539.2363. 
 
(RS) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-
(pyrrolidinyl)methylphenyl]methylisoquinoline (18). 
 
A mixture of the aldehyde 15 (91 mg, 0.194 mmol), pyrrolidine (0.10 mL, 1.13 
mmol), CH3CN (3 mL) and NaCNBH3 (16 mg, 0.252 mmol) was treated as described 
above in the general reductive amination reaction procedure to give an oil. The oil 
was purified by column chromatography (CH3OH/EtOAc (4:6)) to afford 18 (77 mg, 
74%) as a light yellow oil. Compound 18 was a 95:5 mixture of rotamers. Rf. 0.20 
(CH3OH/EtOAc (4: 6)). 
1H NMR of the major rotamer:  6.97 (s, 1H, H3'), 6.59 (s, 
1H, H5), 6.34 (s, 1H, H6'), 6.04 (s, 1H, H8), 5.44 (dd, 1H, J 8.1, 6.1 Hz, H1), 3.93-
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3.87 (m, 1H, H3), 3.87 (s, 3H, OCH3-7), 3.83 (s, 3H, OCH3-5'), 3.80-3.75 (m, 1H, 
H3), 3.69 (s, 3H, OCH3-4'), 3.56 (s, 3H, OCH3-6), 3.42 (d, 1H, J 6.6 Hz, H1''), 3.38 
(d, 1H, J 6.6 Hz, H1''), 3.16 (dd, 1H, 13.5, J 6.1 Hz, H7'), 3.08 (dd, 1H, J 13.5, 8.1 
Hz, H7'), 2.97-2.87 (m, 1H, H4), 2.83-2.74 (m, 5H, H4, H2''', 2xH5'''), 1.92-1.84 (m, 
4H, 2xH3''', 2xH4'''). 1H NMR minor rotamer (in part):  6.79 (s, 1H, H3'), 6.56 (s, 
1H, H5), 6.44 (s, 1H, H6’), 6.04 (s, 1H, H8). 13C NMR of the major rotamer: (signals 
for COCF3 and COCF3 were not observed),  148.3 (C4', C6), 148.1 (C5’), 147.2 
(C7), 128.3 (C2'), 126.9 (C1'), 126.2 (C4a), 125.1 (C8a), 114.4 (CH-6'), 113.5 (CH-
3'), 111.0 (CH-5), 110.7 (CH-8), 56.5 (CH2-1''), 56.2 (OCH3-7), 56.0 (OCH3-5'), 55.8 
(OCH3-4', OCH3-6), 55.7 (CH-1), 53.6 (CH2-2''', CH2-5'''), 40.8 (CH2-3), 38.4 (CH2-
7’), 28.5 (CH2-4), 23.3 (CH2-3''', CH2-4'''). MS (EI
+): m/z 522 (M+, 20%). HRMS 
(ESI+): calcd for C27H34F3N2O5, 523.2420 (MH
+), found 523.2435. 
 
(R,S) 1-[2'-(Diethylamino)methyl-4',5'-dimethoxyphenyl]methyl-2-
trifluoroacetyl-1,2,3,4-dihydro.-6,7-dimethoxyisoquinoline (19). 
 
A mixture of aldehyde 15 (112 mg, 0.239 mmol), diethylamine (0.2 mL, 1.93 mmol), 
CH3CN (3 mL) and NaCNBH3 (16 mg, 0.252 mmol) was treated as described above 
in the general reductive amination reaction procedure to give an oil. The oil was 
purified by column chromatography (CH3OH/EtOAc (4:6)) to afford 19 (83 mg, 75%) 
as a light yellow oil. Compound 19 was a 95:5 mixture of rotamers. Rf. 0.33 
(CH3OH:EtOAc (4:6)). 
1H NMR of the major rotamer:  6.85 (s, 1H, H3'), 6.57 (s, 
1H, H5), 6.56 (s, 1H, H6'), 6.12 (s, 1H, H8), 5.55 (t, 1H, J 7.8, 6.0 Hz, H1), 3.92 (dt, 
1H, J 7.8, 3.3 Hz, H3), 3.82 (s, 6H, OCH3-7, OCH3-5'), 3.76 (s, 3H, OCH3-4'), 3.73-
3.66 (m, 1H, H3), 3.57 (s, 3H, OCH3-6), 3.32 (dd, 1H, J 13.5, 7.8 Hz, H7'), 3.28 (d, 
1H, J 13.5 Hz, H1''), 3.16 (d, 1H, J 13.5 Hz, H1''), 3.04 (dd, 1H, J 13.5, 6.0 Hz, H7'), 
2.98-2.85 (m, 1H, H4), 2.77-2.69 (m, 1H, H4), 2.43 (q, 4H, J 6.9 Hz, 2 x NCH2CH3), 
0.93 (t, 6H, J 6.9 Hz, 2 x NCH2CH3). 
1H NMR of the minor rotamer (in part):   6.79 
(s, 1H, H3'), 5.85 (s, 1H, H8), 3.79 (s, 6H, OCH3-7, OCH3-5'), 3.48 (s, 3H, OCH3-6). 
13C NMR of the major rotamer: (signals for COCF3 and COCF3 were not observed),  
148.4 (C4'), 147.7 (C6), 147.7 (C5'), 147.5 (C7), 128.5 (C2', C8a), 127.2 (C1'), 125.0 
(C4a), 114.0 (CH-3'), 113.6 (CH-6'), 111.2 (CH-5), 110.7 (CH-8), 55.2 (OCH3-7), 
56.1 (OCH3-5'), 55.1 (OCH3-4'), 55.9 (OCH3-6), 55.7 (CH-1), 55.5 (CH2-1''), 46.5 (2 
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x NCH2CH3), 40.6 (CH2-3), 37.7 (CH2-7'), 28.8 (CH2-4), 11.5 (2 x NCH2CH3). MS 
(EI+): m/z 524 (M+, 10%). HRMS (ESI+): calcd for C27H35F3N2O5, 525.2576 (MH
+), 
found 525.2563. 
 
(R,S) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-
(isopropylamino)methylphenyl]methylisoquinoline (20). 
 
A mixture of aldehyde 15 (112 mg, 0.239 mmol), isopropylamine (0.2 mL, 2.33 
mmol), CH3CN (3 mL) and NaCNBH3 (16 mg, 0.252 mmol) was reacted as described 
above in the general reductive amination reaction procedure to give an oil. The oil 
was purified by column chromatography (CH3OH/EtOAc (4:6)) to afford 20 (67 mg, 
64%) as a light yellow oil. Compound 20 was a 95:5 mixture of rotamers. Rf. 0.17 
(CH3OH/EtOAc (4:6)). 
1H NMR of the major rotamer:  6.80 (s, 1H, H3'), 6.57 (s, 
1H, H5), 6.54 (s, 1H, H6'), 6.12 (s, 1H, H8), 5.58 (t, 1H, J 8.1, 6.6 Hz, H1), 3.95-3.85 
(m, 1H, H3), 3.83 (s, 3H, OCH3-7), 3.81 (s, 3H, OCH3-5'), 3.76 (s, 3H, OCH3-4'), 
3.71-3.65 (m, 1H, H3), 3.56 (s, 3H, OCH3-6), 3.48 (d, 1H, J 12.6 Hz, H1''), 3.43 (d, 
1H, J 12.6 Hz, H1''), 3.20 (dd, 1H, J 13.8, 8.1 Hz, H7'), 3.05 (dd, 1H, J 13.8, 6.6 Hz, 
H7'), 2.96-2.85 (m, 1H, H4), 2.82-2.70 (m, 2H, H2'', H4), 1.04 (d, 3H, J 2.4 Hz, 
CH(CH3)CH3), 1.02 (d, 3H, J 2.4 Hz, CH(CH3)CH3). 
1H NMR of the minor rotamer 
(in part):  6.76 (s, 1H, H3’), 5.92 (s, 1H, H8), 3.77 (s, 3H, OCH3-5’), 3.49 (s, 3H, 
OCH3-6). 
13C NMR of the major rotamer: (signals for COCF3 and COCF3 were not 
observed),  148.4 (C4'), 148.0 (C6), 147.9 (C5'), 147.5 (C7), 131.9 (C2'), 127.9 
(C8a), 126.9 (C1'), 125.1 (C4a), 114.1 (CH-3'), 113.1 (CH-6'), 111.2 (CH-5), 110.7 
(CH-8), 56.0 (OCH3-7), 56.1 (OCH3-5'), 55.1 (OCH3-4’), 55.9 (OCH3-6), 55.8 (CH-
1), 49.3 (CH2-1''), 49.2 (CH-2''), 40.7 (CH2-3), 38.0 (CH2-7'), 28.8 (CH2-4), 23.1 
(CH(CH3)CH3), 22.1 (CH(CH3)CH3). MS (EI
+): m/z 510 (M+, 10%). HRMS (ESI+): 
calcd for C26H34F3N2O5, 511.2421 (MH
+), found 511.2395.  
 
(RS) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-
(2''-(morpholino)ethyl)phenyl]methylisoquinoline (21). 
 
A mixture of aldehyde 16 (80 mg, 0.166 mmol), morpholine (0.1 mL, 1.16 mmol), 
CH3CN (6 mL), NaCNBH3 (16 mg, 0.252 mmol) was treated as described above in 
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the general reductive amination reaction procedure to give an oil. The oil was purified 
by column chromatography (CH3OH/EtOAc (4:6)) to afford 21 (59 mg, 64%) as a 
clear oil. Compound 21 was a 95:5 mixture of rotamers. Rf. 0.25 (CH3OH/EtOAc 
(4:6)). 1H NMR of the major rotamer:  6.66 (s, 1H, H3'), 6.57 (s, 1H, H5), 6.52 (s, 
1H, H6'), 6.01 (s, 1H, H8), 5.48 (t, 1H, J 6.9 Hz, H1), 3.92 (dt, 1H, J 13.5, 5.1 Hz, 
H3), 3.81 (s, 6H, OCH3-7, OCH3-5'), 3.72 (s, 3H, OCH3-4'), 3.67 (t, 4H, J 4.7 Hz, 
2xH3''', 2xH4'''), 3.67-3.62 (m, 1H, H3), 3.53 (s, 3H, OCH3-6), 3.05 (d, 2H, J 6.9 Hz, 
2xH7'), 2.96-2.86 (m, 1H, H4), 2.78-2.70 (m, 1H, H4), 2.63-2.57 (m, 1H, H2''), 2.56-
2.49 (m, 1H, H2''), 2.40 (t, 4H, J 4.7 Hz, 2xH2''', 2xH5'''), 2.37-2.25 (m, 2H, 2xH1''). 
1H NMR of the minor rotamer (in part):  6.64 (s, 1H, H3'), 6.56 (s, 1H, H5), 5.75 (s, 
1H, H8), 3.81 (s, 6H, OCH3-7, OCH3-5'), 3.77 (s, 3H, OCH3-4'), 3.45 (s, 3H, OCH3-
6). 13C NMR of the major rotamer:  156.1 (q, J 35.3 Hz, COCF3), 148.5 (C4’), 148.1 
(C6), 147.5 (C5'), 147.4 (C7), 131.5 (C1'), 127.2 (C2’), 126.6 (C4a), 125.2 (C8a), 
116.7 (q, J 286.5 Hz, COCF3), 114.2 (CH-6'), 113.1 (CH-3'), 111.2 (CH-5), 110.9 
(CH-8), 67.2 (CH2-3''', CH2-4'''), 60.5 (CH2-2’’), 55.8 (4 x OCH3), 55.7 (CH-1), 53.9 
(CH2-2''', CH2-5'''), 40.9 (CH2-3), 38.2 (CH2-7'), 29.7 (CH2-1''), 28.7 (CH2-4).
 13C 
NMR of the minor rotamer (in part):  147.9 (C5'), 147.1 (C7), 131.8 (C1'), 127.0 
(C2'), 126.0 (C4a), 111.2 (CH-5), 110.4 (CH-8), 65.9 (CH2-3''', CH2-4'''), 60.1 (CH2-
2''), 53.8 (CH2-2''', CH2-5'''), 40.9 (CH2-3), 39.2 (CH2-7'), 31.8 (CH2-1''), 27.4 (CH2-
4). MS (ESI+): m/z 552.81 (MH+, 100%). HRMS (ESI+): calcd for C28H36F3N2O6, 
553.2525 (MH+), found 553.2486. 
 
(RS) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-6,7-dimethoxy-1-[4',5'-Dimethoxy-2'-
(2''-(N-pyrolidinyl)ethyl)phenyl]methylisoquinoline (22). 
 
A mixture of aldehyde 16 (71 mg, 0.149 mmol), pyrrolidine (0.2 mL, 2.26 mmol), 
CH3CN (3 mL) and NaCNBH3 (12 mg, 0.194 mmol) was treated as described above 
in the general reductive amination reaction procedure to give an oil. The oil was 
purified by column chromatography (CH3OH/ EtOAc (4:6)) to afford 22 (61 mg, 
74%) as a light yellow oil. Compound 22 was a 95:5 mixture of rotamers. Rf. 0.20 
(CH3OH/EtOAc (4:6)). 
1H NMR of the major rotamer:  6.64 (s, 1H, H3'), 6.60 (s, 
1H, H5), 6.56 (s, 1H, H6'), 6.02 (s, 1H, H8), 5.50 (dd, 1H, J 8.4, 5.7 Hz, H1), 3.93 (dt, 
1H, J 13.8, 5.4 Hz, H3), 3.89 (s, 6H, OCH3-7, OCH3-5'), 3.76 (s, 3H, OCH3-4’), 3.71-
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3.62 (m, 1H, H3), 3.53 (s, 3H, OCH3-6), 3.05 (dd, 1H, J 13.5, 8.4 Hz, H7'), 3.02 (dd, 
1H, J 13.5, 5.7 Hz, H7'), 2.96-2.81 (m, 1H, H4), 2.78-2.69 (m, 1H, H4), 2.58-2.35 (m, 
8H, 2xH2''', 2xH5''', 2xH1'', 2xH2''), 1.80-1.76 (m, 4H, 2xH3''', 2xH4'''). 1H NMR of 
the minor rotamer (in part): 6.61 (s, 1H, H3'), 5.75 (s, 1H, H8), 3.39 (s, 3H, OCH3-6). 
13C NMR of the major rotamer: (signals for COCF3 and COCF3 were not observed),  
148.2 (C4'), 148.8 (C6), 147.2 (C5', C7), 131.44 (C2’), 127.0 (C4a), 126.3 (C1'), 
124.8 (C8a), 113.6 (CH-5), 111.7 (CH-3'), 110.9 (CH-6'), 110.4 (CH-8), 57.7 (CH2-
2''), 55.9 (OCH3-7, OCH3-5'), 55.6 (OCH3-4', OCH3-6, CH-1), 54.0 (CH2-2''', CH2-
5'''), 40.5 (CH2-3), 37.8 (CH2-7’), 31.9 (CH2-1''), 28.5  (CH2-4), 23.4 (CH2-3''', CH2-
4'''). MS (EI+): m/z 536  (M+, 10%). HRMS (ESI+): calcd for C28H36F3N2O5, 537.2576 
(MH+), found 537.2581. 
 
(RS) 1-[2'-(2''-(Diethylamino)ethyl)-4',5'-dimethoxyphenyl]methyl-2-
trifluoroacetyl-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline (23). 
 
A mixture of aldehyde 16 (132 mg, 0.274 mmol), diethylamine (0.2 mL, 1.93 mmol), 
CH3CN (3 mL) and NaCNBH3 (22 mg, 0.356 mmol) was treated as described above 
in the general reductive amination reaction procedure to give an oil. The oil was 
purified by column chromatography (CH3OH/EtOAc (4:6)) to afford 23 (100 mg, 
68%) as a light yellow oil. Compound 23 was a 95:5 mixture of rotamers. Rf. 0.21 
(CH3OH/EtOAc (4:6)). 
1H NMR of the major rotamer:  6.63 (s, 1H, H3'), 6.57 (s, 
2H, H5, H6'), 6.03 (s, 1H, H8), 5.49 (dd, 1H, J 8.4, 6.0 Hz, H1), 3.93 (dt, 1H, J 13.5, 
5.7 Hz, H3), 3.82 (s, 3H, OCH3-7), 3.82 (s, 3H, OCH3-5'), 3.75 (s, 3H, OCH3-4'), 
3.71-3.64 (m, 1H, H3), 3.54 (s, 3H, OCH3-6), 3.10 (dd, 1H, J 13.5, 8.4 Hz, H7'), 3.03 
(dd, 1H, J 13.5, 6.0 Hz, H7'), 2.94-2.86 (m, 1H, H4), 2.79-2.71 (m, 1H, H4), 2.55 (q, 
4H, J 6.9 Hz, 2 x NCH2CH3), 2.59-2.42 (m, 4H, 2xH1'', 2xH2''), 1.01 (t, 6H, J 6.9 Hz,  
2 x NCH2CH3). 
1H NMR of the minor rotamer (in part):  6.60 (s, 1H, H3'), 3.52 (s, 
3H, OCH3-6). 
13C NMR of the major rotamer:  155.6 (q, J 36.2 Hz, COCF3), 148.2 
(C4'), 147.89 (C6), 147.2 (C5', C7), 131.5 (C2'), 127.0 (C4a), 126.3 (C1'), 124.9 
(C8a), 116.0 (q, J 286.3 Hz, COCF3), 113.8 (CH-5), 112.8 (CH-3'), 110.9 (CH-6'), 
110.5 (CH-8), 55.9 (OCH3-7, OCH3-5', CH-1), 54.6 (OCH3-4', OCH3-6), 54.2 (CH2-
2''), 46.6 (2 x NCH2CH3), 40.7 (CH2-3), 38.0 (CH2-7'), 29.6 (CH2-1''), 28.5 (CH2-4), 
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11.5  (2 x NCH2CH3). MS (EI
+): m/z 538  (M+, 10%). HRMS (ESI+): calcd for 
C28H38N2O5F3, 539.2733 (MH
+), found 539.2734. 
General method for N-Trifluoroacetyl deprotection and reductive N-
Methylation. 
The N-TFA protected amine was dissolved in a mixture of CH3OH and H2O. To 
this was added K2CO3 and the resulting solution was stirred at rt for 18 h. CH3OH 
was removed and the residue was dissolved in CH3CN. 38 % Formaldehyde was 
added followed by NaCNBH3. Glacial acetic acid was added after 20 min of stirring 
to adjusted the pH to ~ 6. The reaction mixture was stirred at rt for 18 h. CH3CN was 
evaporated and the residue was redissolved in CH2Cl2. The CH2Cl2 layer was washed 
with sat. K2CO3 and dried (MgSO4). Evaporation of the CH2Cl2 extracts gave the 
crude product which was purified by column chromatography to afford the pure N-
methylated analogues. 
 
(RS) 1,2,3,4-Tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-
(morpholino)methyl phenyl]methyl-2-methylisoquinoline (24). 
 
The N-TFA protected amine 17 (40 mg, 0.074 mmol) was treated as described above 
in the general N-TFA deprotection and reductive N-methylation reaction procedure by 
initially using K2CO3 (50 mg, 0.370 mmol), CH3OH (5 mL) and H2O (1 mL), except 
it was stirred at 80 0C for 3 h, then using 38 % formaldehyde (3 mL), CH3CN (3 mL) 
and NaCNBH3 (6 mg, 0.096 mmol) to give an oil. The oil was purified by column 
chromatography (CH3OH/EtOAc/NH3 (4:6:0.1)) to afford 24 (25 mg, 73%) as a clear 
oil. Rf. 0.34 (CH3OH/EtOAc/NH3 (4:6: 0.1)). 
1H NMR:  6.80 (s, 1H, H3'), 6.58 (s, 
1H, H5), 5.41 (s, 1H, H6'), 5.71 (s, 1H, H8), 3.85 (s, 3H, OCH3-7), 3.84 (s, 3H, 
OCH3-5'), 3.81 (dd, 1H, J 9.0, 5.2 Hz, H1), 3.76 (s, 3H, OCH3-4'), 3.66 (t, 4H, J 2.7 
Hz, 2xH3''', 2xH4'''), 3.44 (s, 3H, OCH3-6), 3.29-3.25 (m, 1H, H3), 3.19 (d, 1H, J 12.9 
Hz, H1''), 3.17 (dd, 1H, J 13.5, 5.2 Hz, H7'), 2.96 (dd, 1H, J 13.4, 9.0 Hz, H7'), 3.07 
(d, 1H, J 12.9 Hz, H1''), 2.88-2.85 (m, 1H, H4), 2.81 (dt, 1H, J 9.3, 3.0 Hz, H3), 2.63 
(dd, 1H, J 5.7, 3.0 Hz, H4), 2.56 (s, 3H, NCH3), 2.36 (t, 4H, J 2.7 Hz,  H2''', H5'''). 
MS (ESI+): m/z 457.1  (MH+, 40%). HRMS (ESI+): calcd for C27H39N2O5, 471.2859 
(MH+), found 471.2865. 
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(RS) 1,2,3,4-Tetrahydro-6,7-dimethoxy 1-[4',5'-dimethoxy-2'-
(pyrrolidinyl)methyl phenyl]methyl-2-methylisoquinoline (25). 
 
The N-TFA protected amine 18 (79 mg, 0.148 mmol) was treated as described above 
in the general N-TFA deprotection and reductive N-methylation reactions procedure 
by initially using K2CO3 (101 mg, 0.740 mmol), CH3OH (5 mL) and H2O (1 mL) and 
then 38 % formaldehyde (3mL), CH3CN (3 mL) and NaCNBH3 (20 mg, 0.328 mmol) 
to give an oil. The oil was purified by column chromatography (CH3OH/EtOAc/NH3 
(4:6:0.1)) to afford 25 (48 mg, 71% yield) as a light yellow oil. Rf. 0.34 
(CH3OH/EtOAc/NH3 (4:6:0.1)). 
1H NMR:  6.91(s, 1H, H3'), 6.55 (s, 1H, H5), 5.44 
(s, 1H, H6'), 5.76 (s, 1H, H8), 3.85 (s, 3H, OCH3-7), 3.81 (s, 3H, OCH3-5'), 3.86-3.80 
(m, 1H, H1), 3.72 (s, 3H, OCH3-6), 3.49 (d, 1H, J 12.9 Hz, H1''), 3.44 (s, 3H, OCH3-
4’), 3.29 (d, 1H, J 12.9 Hz, H1''), 3.23-3.11 (m, 2H, H3, H7'), 2.94-2.78 (m, 3H, H7', 
H3, H4), 2.63-2.54 (m, 1H, H4), 2.52 (s, 3H, NCH3), 2.41 (bs, 4H, 2xH2''', 2xH5'''), 
1.70 (bs, 4H, 2xH3’’’, 2xH4’’’).13C NMR:  147.5 (C4', C6), 147.2 (C5'), 147.2 (C7), 
130.8 (C2', C4a), 129.4 (C1'), 125.9 (C8a), 114.9 (CH-5), 113.4 (CH-3'), 111.8 (CH-
6'), 111.5 (CH-8), 64.1 (CH-1), 57.8 (CH2-1''), 56.3 (OCH3-7), 56.1 (OCH3-5', OCH3-
4'), 55.5 (OCH3-6), 54.3 (CH2-2''', CH2-5'''), 46.3 (CH2-3), 42.7 (NCH3), 37.1 (CH2-
7’), 25.1 (CH2-4), 23.8  (CH2-3''', CH2-4'''). MS (ESI
+): m/z 441.1 (MH+, 100%). 
HRMS (ESI+): calcd for C26H36N2O4, 441.2753 (MH
+), found 441.2777.  
 
(RS) 1-[2'-(Diethylamino)methyl-4',5'-dimethoxyphenyl]methyl-1,2,3,4-
tetrahydro-6,7-dimethoxy-2-methylisoquinoline (26). 
 
The N-TFA protected amine 19 (75 mg, 0.161 mmol) was treated as described above 
in the general N-TFA deprotection and reductive N-methylation reaction procedure by 
initially using K2CO3 (109 mg, 0.810 mmol), CH3OH (2 mL) and H2O (1 mL), except 
it was stirred for 4 h and then using 38 % formaldehyde (3 mL), CH3CN (3 mL) and 
NaCNBH3 (20 mg, 0.328 mmol) to give an oil. The oil was purified by column 
chromatography (CH3OH/EtOAc/NH3 (4:6:0.1)) to afford 26 (41 mg, 58%) as a light 
yellow oil. Rf. 0.32 (CH3OH/EtOAc/NH3 (4:6:0.1)). 
1H NMR:  6.88 (s, 1H, H3'), 
6.54 (s, 1H, H5), 5.51 (s, 1H, H6’), 5.69 (s, 1H, H8), 3.83 (s, 3H, OCH3-7), 3.80 (s, 
3H, OCH3-5'), 3.74 (s, 3H, OCH3-6), 3.70 (dd, 1H, J 9.0, 4.8 Hz, H1), 3.40 (s, 3H, 
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OCH3-4'), 3.31-3.24 (m, 1H, H3), 3.18 (d, 1H, J 13.5 Hz, H1''), 3.08 (dd, 2H, J 13.5, 
4.8 Hz, H7'), 2.98 (d, 1H, J 13.5 Hz, H1''), 2.89 (dd, 1H, J 9.6, 3.0 Hz, H3), 2.84 (dd, 
1H, J 13.5, 9.0 Hz, H7'), 2.80-2.76 (m, 1H, H4), 2.60-2.56 (m, 1H, H4), 2.54 (s, 3H, 
NCH3), 2.49-2.29 (m, 4H, 2 x NCH2CH3), 0.90 (t, 6H, J 6.9 Hz, 2 x NCH2CH3). 
13C 
NMR:  147.3 (C4'), 147.2 (C6), 146.9 (C5'), 145.9 (C7), 131.1 (C2'), 130.7 (C4a), 
128.9 (C1'), 125.6 (C8a), 114.8 (CH-5), 113.1 (CH-3'), 111.3 (CH-6'), 111.2 (CH-8), 
64.1 (CH-1), 56.0 (CH2-1''), 55.9 (OCH3-7), 55.8 (OCH3-5'), 55.3 (OCH3-4'), 55.0 
(OCH3-6), 46.6 (2 x NCH2CH3), 46.0 (CH2-3), 42.5 (NCH3), 36.5 (CH2-7'), 25.1 
(CH2-4), 11.6 (2 x NCH2CH3). MS (ESI
+): m/z 443.2 (MH+, 100%). HRMS (ESI+) 
calcd for C26H39N2O4, 443.2910 (MH
+), found 443.2928. 
 
(RS) 1,2,3,4-Tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-(2''-
(isopropylamino)methyl)phenyl]methyl-2-methylisoquinoline (27). 
 
The N-TFA protected amine 20 (60 mg, 0.136 mmol) was treated as described above 
in the general N-TFA deprotection and reductive N-methylation reaction procedure by 
initially using K2CO3 (91 mg, 0.680 mmol), CH3OH (3 mL) and H2O (1 mL), except 
it was stirred for 4 h, and then using 38 % formaldehyde (3 mL), CH3CN (3 mL) and 
NaCNBH3 (20 mg, 0.328 mmol) to give an oil. The oil was purified by column 
chromatography (CH3OH/EtOAc/NH3 (4:6:0.1)) to afford 27 (36 mg, 59%) as a light 
yellow oil . Rf. 0.34 (CH3OH/EtOAc/NH3 (4:6:0.1)).1H NMR:  6.82 (s, 1H, H3'), 
6.54 (s, 1H, H5), 5.52 (s, 1H, H6'), 5.67 (s, 1H, H8), 3.82 (s, 3H, OCH3-7), 3.80 (s, 
3H, OCH3-5'), 3.75 (s, 3H, OCH3-6), 3.76-3.70 (m, 1H, H1), 3.39 (s, 3H, OCH3-4'), 
3.32-3.20 (m, 1H, H3), 3.12 (d, 1H, J 12.9 Hz, H1''), 2.95 (d, 1H, J 12.9 Hz, H1''), 
2.96-2.77 (m, 5H, H4, 2xH7’, H3, H2''), 2.61-2.52 (m, 1H, H4), 2.54 (s, 3H, NCH3), 
0.94 (t, 6H, J 2.1 Hz, CH(CH3)CH3).
13C NMR:  147.6 (C4'), 147.5 (C6), 147.2 (C5'), 
146.0 (C7), 130.5 (C2', C4a), 128.0 (C1’), 125.1 (C8a), 114.3 (CH-5), 113.4 (CH-3'), 
111.3 (CH-6'), 111.1 (CH-8), 64.2 (CH-1), 56.1 (OCH3-7), 55.9 (OCH3-5'), 55.8 
(OCH3-4'), 55.3 (OCH3-6), 54.4 (CH2-1''), 53.2 (CH-2'''), 45.9 (CH2-3), 36.7 (CH2-
7'), 35.8 (NCH3), 24.9 (CH2-4), 17.7 (CH(CH3)CH3), 17.2 (CH(CH3)CH3). MS 
(ESI+): m/z 443.1 (MH+, 100%). HRMS (ESI+): calcd for C26H39N2O4, 443.2910 
(MH+), found 443.2910. 
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(RS) 1,2,3,4-Tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-(2'''-
(morpholino)ethyl)phenyl]methyl-2-methylisoquinoline (1). 
 
The N-TFA protected amine 21 (50 mg, 0.092 mmol) was treated as described above 
in the general N-TFA deprotection and reductive N-methylation reaction procedure by 
initially using K2CO3 (91 mg, 0.68 mmol), CH3OH (3 mL) and H2O (1 mL), then 38% 
formaldehyde (3 mL), CH3CN (3 mL) and NaCNBH3 (10 mg, 0.164 mmol) to give an 
oil. The oil was purified by column chromatography (CH3OH/EtOAc/NH3 (4:6:0.1)) 
to afford 11 (37 mg, 85%) as a light yellow oil. Rf. 0.30 (CH3OH/EtOAc/NH3 (4 : 6 : 
0.1)). 1H NMR:  6.61 (s, 1H, H3'), 6.55 (s, 1H, H5), 6.53 (s, 1H, H6'), 5.68 (s, 1H, 
H8), 3.80 (s, 3H, OCH3-7), 3.78 (s, 3H, OCH3-5'), 3.75 (s, 3H, OCH3-4'), 3.67 (t, 4H, 
J 4.5 Hz, 2H2''', 2H5'''), 3.65-3.62 (m, 1H, H1), 3.38 (s, 3H, OCH3-6), 3.28-3.20 (m, 
1H, H3), 3.15 (dd, 1H, J 13.2, 4.2 Hz, H7'), 2.94-2.87 (m, 1H, H4), 2.85-2.81 (m, 1H, 
H3), 2.74 (dd, 1H, J 13.2, 9.6 Hz, H7'), 2.61-2.54 (m, 1H, H4), 2.53 (s, 3H, NCH3), 
2.38 (t, 4H, J 5.1 Hz, 2xH3''', 2xH4'''), 2.34-2.27 (m, 2H, H2''), 2.24-2.17 (m, 2H, 
H1''). 13C NMR:  147.4 (C4'), 147.3 (C6), 147.1 (C5'), 146.0 (C7), 131.0 (C2'), 129.4 
(C4a), 128.1 (C1'), 125.2 (C8a), 114.0 (CH-5), 112.8 (CH-3'), 111.2 (CH-6', CH-8), 
66.8 (CH2-3''', CH2-4'''), 64.3 (CH-1), 59.9 (CH2-2''), 55.9 (OCH3-7), 55.9 (OCH3-5'), 
55.7 (OCH3-4'), 55.3 (OCH3-6), 53.5 (CH2-2''', CH2-5'''), 45.9 (CH2-3), 42.2 (NCH3), 
37.1 (CH2-7'), 29.5 (CH2-1''), 24.7 (CH2-4).
 MS (ESI+): m/z 471.1  (MH+, 40%). 
HRMS (ESI+): calcd for C27H39N2O5, 471.2859 (MH
+), found 471.2865. 
 
(RS) 1,2,3,4-Tetrahydro-6,7-dimethoxy-1-[4',5'-dimethoxy-2'-(2'''-
(pyrolidino)ethyl) phenyl]methyl-2-methylisoquinoline (28). 
 
The N-TFA protected amine 22 (38 mg, 0.076 mmol) was treacted as described above 
in the general N-TFA deprotection and reductive N-methylation reaction procedure by 
using initially K2CO3 (52 mg, 0.381 mmol), CH3OH (5 mL) and H2O (1 mL), then 
38% formaldehyde (3 mL), CH3CN (3 mL) and NaCNBH3 (10 mg, 0.164 mmol) to 
give an oil. The oil purified by column chromatography (CH3OH/EtOAc/NH3 
(4:6:0.1)) to afford 28 (25 mg, 69%) as a light yellow oil. Rf. 0.30 
(CH3OH/EtOAc/NH3 (4:6:0.1)). 
1H NMR:  6.63 (s, 1H, H3'), 6.56 (s, 1H, H5), 6.54 
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(s, 1H, H6'), 5.74 (s, 1H, H8), 3.81 (s, 3H, OCH3-7), 3.80 (s, 3H, OCH3-5'), 3.76 (s, 
3H, OCH3-4'), 3.66 (dd, 1H, J 9.0, 4.5 Hz, H1), 3.42 (s, 3H, OCH3-6), 3.24 (m, 1H, 
H3), 3.09 (dd, 1H, J 13.5, 4.5 Hz, H7'), 2.94-2.87 (m, 1H, H4), 2.82-2.74 (m, 1H, 
H3), 2.78 (dd, 1H, J 13.5, 9.0 Hz, H7'), 2.61-2.58 (m, 1H, H4), 2.54 (s, 3H, NCH3), 
2.52-2.30 (m, 8H, 2xH1'', 2xH2’’, 2xH2''', 2xH5'''), 1.75 (t, 4H, J 3.9 Hz, 2xH3''', 
2xH4'''). 13C NMR:  149.4 (C4'), 148.9 (C6), 148.4 (C5'), 147.0 (C7), 128.4 (C2'), 
126.3 (C4a), 121.5 (C1'), 120.2 (C8a), 115.0 (CH-5), 113.0 (CH-3'), 111.7 (CH-6'), 
111.5 (CH-8), 65.2 (CH2-2''), 56.4 (OCH3-7, OCH3-5'), 56.2 (OCH3-4'), 55.6 (OCH3-
6), 53.3 (CH2-1),  47.1 (CH2-2''', CH2-5'''), 45.3 (CH2-3), 44.3 (NCH3), 40.0 (CH2-7'), 
37.8 (CH2-1''), 27.4 (CH2-4), 21.4 (CH2-3''', CH2-4'''). MS (ESI
+): m/z 454.92 (MH+, 
20%). HRMS (ESI+): calcd for C27H39N2O4, 455.2910 (MH
+), found 455.2907. 
 
(RS) 1-[2'-(2'''-(Diethylamino)ethyl)-4',5'-dimethoxyphenyl]methyl-1,2,3,4-
tetrahydro-6,7-dimethoxy-2-methylisoquinoline (29). 
 
The N-TFA protected amine 23 (80 mg, 0.149 mmol) was treated as described above 
in the general N-TFA deprotection and reductive N-methylation reaction procedure by 
initially using K2CO3 (100 mg, 0.735 mmol), CH3OH (5 mL) and H2O (1 mL), then 
38% formaldehyde (3 mL), CH3CN (3 mL) and NaCNBH3 (20 mg, 0.328 mmol) to 
give an oil. The oil was purified by column chromatography (CH3OH/EtOAc/NH3 
(4:6:0.1)) to afford 29 (65 mg, 69%) as a light yellow oil.  Rf. 0.31 
(CH3OH/EtOAc/NH3 (4:6:0.1)). 
1H NMR:  6.61 (s, 1H, H3'), 6.57 (s, 1H, H5), 6.54 
(s, 1H, H6'), 5.71 (s, 1H, H8), 3.81 (s, 3H, OCH3-7), 3.79 (s, 3H, OCH3-5'), 3.76 (s, 
3H, OCH3-4'), 3.66 (dd, 1H, J 9.0, 4.2 Hz, H1), 3.40 (s, 3H, OCH3-6), 3.27-3.21 (m, 
1H, H3), 3.09 (dd, 1H, J 13.0, 4.2 Hz, H7'), 2.92-2.86 (m, 1H, H4), 2.83-2.78 (m, 1H, 
H3), 2.78 (dd, 1H, J 13.0, 9.0 Hz, H7'), 2.59-2.54 (m, 1H, H4), 2.55 (s, 3H, NCH3), 
2.52 (q, 4H, J 4.2 Hz, 2 x NCH2CH3), 2.52-2.44 (m, 2H, 2xH2''), 2.35 (dt, 2H, J 12.3, 
4.1 Hz, 2xH1''), 1.00 (t, 6H, J 4.2 Hz, 2 x NCH2CH3). 
13C NMR:  148.2 (C4', C6), 
148.0 (C5'), 146.5 (C7), 129.0 (C2', C4a), 125.9 (C1’), 124.8 (C8a), 114.0 (CH-5), 
112.7 (CH-3'), 111.2 (CH-6’), 111.0 (CH-8), 64.5 (CH-1), 56.0 (OCH3-7, OCH3-5'), 
55.7 (OCH3-4', OCH3-6), 55.2 (CH2-2''), 45.9 (2 x NCH2CH3), 45.3 (CH2-3), 41.2 
(NCH3), 36.8 (CH2-7'), 27.3 (CH2-1''), 23.4 (CH2-4), 8.8 (2 x NCH2CH3). MS (ESI
+): 
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m/z 456.94 (MH+, 30%). HRMS (ESI+): calcd for C27H41N2O4, 457.3066 (MH
+), 
found 457.3060. 
 
 (RS) 1,2,3,4-Tetrahydro-6,7-dimethoxy-1[2'-((2''',2'''-
diethoxyethylamino)methy)-4’,5’-dimethoxyphenyl]methylisoquinoline (31). 
 
The aldehyde 15 was freshly generated from the diol 13 (139 mg, 0.278 mmol) as 
described in the general oxidative cleavage reaction procedure using a suspension of 
silica gel coated with NaIO4, using NaIO4 (827 mg, 3.89 mmol), H2O (2 mL), silica 
gel (1.7 g) and CH2Cl2 (5 mL). To the solution of the aldehyde 15 in CH3CN (4 mL) 
was added aminoacetaldehyde diethylacetal (487 mg, 3.67 mmol, 0.5 mL) and 
NaCNBH3 (12 mg, 0.475 mmol). The reaction mixture was stirred at rt for 20 min and 
the pH was adjusted to ~ 6 using glacial acetic acid. The reaction mixture was stirred 
for 18 h at rt. The CH3CN was evaporated and the residue was dissolved in a mixture 
of CH3OH (10 mL) and H2O (3 mL). K2CO3 (100 mg, 0.737 mmol)  was added and 
the mixture was stirred at rt for 18 h. CH3OH was evaporated and the residue was 
dissolved in CH2Cl2. The solution was washed with H2O (3x), brine and dried 
(K2CO3) to give an oil which was purified by column chromatography (EtOAc 
increase to CH3OH/EtOAc/NH3 (3:7:0.1)) to give 31 (118 mg, 82% over 3 steps) as a 
yellow oil. Rf. 0.07 (CH3OH/EtOAc (5:5)). 
1H NMR: (500 MHz)  6.84 (s, 1H, H3'), 
6.61 (s, 1H, H5), 6.60 (s, 1H, H6'), 6.54 (s, 1H, H8), 4.61 (t, 1H, J 5.0 Hz, H2'''), 4.19 
(dd, 1H, J 8.0, 4.5 Hz, H1), 3.83 (s, 3H, OCH3-7), 3.81 (s, 3H, OCH3-5'), 3.83-3.70 
(m, 2H, 2H3), 3.78 (s, 3H, OCH3-4'), 3.75 (s, 3H, OCH3-6), 3.65 (dq, 2H, J 14.5, 6.5, 
OCHHCH3), 3.50 (dq, 2H, J 14.5, 6.5, OCHHCH3), 3.22 (dd, 1H, J 13.5, 4.5 Hz, 
H7'), 3.07 (dd, 1H, J 12.5, 6.5 Hz, H1''), 2.89-2.84 (m, 2H, H7’, H1''), 2.76 (d, 2H, J 
5.0 Hz, 2xH1'''), 2.64-2.62 (m, 2H, 2xH4), 1.14 (t, 6H, J 6.5 Hz, 2 x OCH2CH3). 13C 
NMR:  147.7 (C4’), 147.3 (C6), 147.1 (C5'), 146.9 (C7), 130.1 (C2'), 129.5 (C8a), 
129.1 (C1'), 127.1 (C4a), 113.1 (CH-5), 112.8 (CH-3'), 111.4 (CH-6'), 109.3 (CH-8), 
101.6 (CH-2'''), 62.1 (2 x OCH2CH3), 55.8 (CH-1), 55.9 (OCH3-7), 55.6 (OCH3-5', 
OCH3-4'), 55.5 (OCH3-6), 51.4 (CH2-1'''), 50.7 (CH2-3), 40.4 (CH2-1''), 38.6 (CH2-7'), 
28.8 (CH2-4), 15.0 (2 x OCH2CH3). MS (ESI
+): m/z 488.6 (MH+, 100%). 
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Attempted synthesis of (RS) 1,2,3,4-tetrahydro-1[4',5'-dimethoxy-2'-(2-
oxoethylamino)methyphenyl]methyl-6,7-dimethoxyisoquinoline  (32). 
 
To a solution of 31 (71.3 mg, 0.146 mmol) in a mixture of CH3OH (2 mL) and H2O (1 
mL) was added TsOH (75.3 mg, 0.438 mmol) to bring the pH to ~ 3. The reaction 
mixture was stirred at rt for 18 h. ESMS indicated only the unreacted 31.  The 
reaction was heated at 80 oC for 18 h, however only the precursor 31 was recovered 
and none of the desired aldehyde 32 was obtained.  
 
(RS) 1,2,3,4-Tetrahydro-1[4',5'-dimethoxy-2'-(2,2-dimethoxyethylamino)methyl 
phenyl]methyl-6,7-dimethoxyisoquinoline  (33). 
 
To a solution of the amine 31 (116 mg, 0.225 mmol) in CH3OH (3 mL) was added 
10% aqueous HCl (1 mL). The mixture was heated at reflux for 4 h. The solution was 
basified with K2CO3 (excess) to about pH ~6. The CH3OH was evaporated and the 
residue was dissolved in CH2Cl2. The solution was washed with H2O (3 x), brine and 
dried (K2CO3) to give 33 (37 mg, 41%) as a yellow oil. Rf. 0.1 (CH3OH/EtOAc/NH3 
(5:5:0.1)). 1H NMR:  6.86 (s, 1H, H3'), 6.75 (s, 1H, H5), 6.65 (s, 1H, H6'), 6.60 (s, 
1H, H8), 4.51 (t, 1H, J 5.3 Hz, H2'''), 4.26 (dd, 1H, J 8.7, 3.9 Hz, H1), 3.86 (s, 3H, 
OCH3-7), 3.83 (s, 3H, OCH3-5'), 3.81 (s, 3H, OCH3-4'), 3.84-3.78 (m, 2H, 2xH3), 
3.79 (s, 3H, OCH3-6), 3.37 (s, 6H, 2 x OCH3), 3.32-3.27 (m, 1H, H7'), 3.11 (dd, 1H, J 
12.6, 4.2 Hz, H1''), 2.94-2.89 (m, 2H, H7’, H1''), 2.80 (dd, 2H, J 5.3, 2.1 Hz, 2xH1'''), 
2.72-2.66 (m, 2H, 2xH4). 13C NMR:  148.4 (C4'), 148.3 (C6), 147.9 (C5'), 147.7 
(C7), 133.4 (C2'), 129.4 (C8a), 128.6 (C1'), 127.6 (C4a), 114.7 (CH-5), 113.6 (CH-
3'), 111.9 (CH-6'), 109.8 (CH-8), 103.8 (CH-2'''), 56.2 (OCH3-7, OCH3-5'), 56.1 
(OCH3-4', OCH3-6), 54.6 (CH-1), 54.5 (2x OCH3), 51.3 (CH2-1'''), 53.9 (CH2-3), 40.9 
(CH2-1''), 39.1 (CH2-7'), 29.0 (CH2-4). MS (ESI+): m/z 461.1 (MH+, 50%). 
 
 (RS) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-1[4',5'-dimethoxy-2'-
(methylamino)methylphenyl]methyl-6,7-dimethoxyisoquinoline  (36). 
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To a solution of the aldehyde 15 (136 mg, 0.290 mmol) and 33 % aqueous 
methylamine (0.05 mL) in CH3CN (3 mL) was added NaCNBH3 (24 mg, 0.377 
mmol). The reaction was stirred at rt for 20 min before the pH was adjusted to ~ 6 
using glacial acetic acid. The resulting solution was stirred for 18 h at rt. The CH3CN 
was evaporated and the residue was dissolved in CH2Cl2. The solution was washed 
with H2O (3x), sat. Na2CO3, brine and dried (MgSO4) to give an oil. The oil was 
purified by column chromatography (CH3OH/EtOAc/NH3 (5:5:0.1)) to afford 36 as a 
clear oil (100 mg, 71%). Compound 36 was a 95:5 mixture of rotamers. Rf. 0.35 
(CH3OH/EtOAc/NH3 (5:5:0.1)). 1H NMR of the major rotamer (500 MHz):  6.83 (s, 
1H, H3'), 6.57 (s, 1H, H5), 6.48 (s, 1H, H6'), 6.08 (s, 1H, H8), 5.53 (t, 1H, J 7.0 Hz, 
H1), 3.89 (dt, 1H, J 13.5, 4.5 Hz, H3), 3.82 (s, 3H, OCH3-7), 3.80 (s, 3H, OCH3-5'), 
3.72 (s, 3H, OCH3-4'), 3.69 (dt, 1H, J 13.5, 3.5 Hz, H3), 3.54 (s, 3H, OCH3-6), 3.50 
(bs, 2H, 2xH1''), 3.11 (d, 2H, J 7.0 Hz, 2xH7'), 2.96-2.85 (m, 1H, H4), 2.80-2.72 (m, 
1H, H4), 2.37 (s, 3H, NCH3). 
1H NMR of the minor rotamer (in part):  6.77 (s, 1H, 
H3'), 6.53 (s, 1H, H5), 6.52 (s, 1H, H6'), 5.95 (s, 1H, H8), 5.09 (t, 1H, J 6.0 Hz, H1), 
4.56 (dd, 1H, J 6.5 Hz, H3), 3.75 (s, 3H, OCH3-5'). 13C NMR of the major rotamer:  
156.0 (q, J 36.5 Hz, COCF3), 148.1 (C4'), 147.7 (C6), 147.7 (C5'), 147.2 (C7), 130.4 
(C2'), 127.7 (C8a), 126.5 (C1'), 124.8 (C4a), 116.4 (q, J 287.5 Hz, COCF3), 114.0 
(CH-5), 112.7 (CH-3'), 110.9 (CH-6'), 110.6 (CH-8), 58.9 (OCH3-7), 55.8 (OCH3-5'), 
55.8 (OCH3-4'), 55.6 (CH-1), 55.5 (OCH3-6), 52.8 (CH2-1''), 40.6 (CH2-3), 37.8 
(CH2-7'), 36.0 (NCH3), 28.4 (CH2-4). MS (ESI+): m/z 483 (MH+, 30%). HRMS 
(ESI+): calcd for C24H30N2O5F3, 483.2107 (MH
+), found 483.2135. 
 
(RS) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-1[4',5'-dimethoxy-2'-
(methylamino)ethyl phenyl]methyl-6,7-dimethoxyisoquinoline  (37). 
 
A mixture of aldehyde 16 (131 mg, 0.272 mmol) and 33 % aqueous methylamine 
(0.05 mL) in CH3CN (3 mL) was added NaCNBH3 (22 mg, 0.354 mmol). The 
mixture was treated as described above for the synthesis of 36 to give an oil. The oil 
was purified by column chromatography (CH3OH/EtOAc/NH3 (5:5:0.1)) to afford 37 
as a yellow oil (82 mg, 62% yield). Compound 37 was a 95:5 mixture of rotamers. Rf. 
0.25 (CH3OH/EtOAc/NH3 (5 : 5 : 0.1)). 
1H NMR of the major rotamer:  6.65 (s, 1H, 
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H3’), 6.58 (s, 1H, H5), 6.53 (s, 1H, H6'), 5.98 (s, 1H, H8), 5.48 (t, 1H, J 6.0 Hz, H1), 
3.93 (dt, 1H, J 13.5, 5.0 Hz, H3), 3.82 (s, 6H, OCH3-7, OCH3-5'), 3.73 (s, 3H, OCH3-
4'), 3.69 (td, 1H, J 12.5, 3.0 Hz, H3), 3.52 (s, 3H, OCH3-6), 3.08 (d, 2H, J 6.0 Hz, 
2xH7'), 2.95-2.88 (m, 1H, H4), 2.81-2.76 (m, 1H, H4), 2.64 (t, 2H, J 6.5 Hz, 2xH2''), 
2.63-2.58 (m, 1H, H1''), 2.55 (dd, 1H, J 13.5, 6.5 Hz, H1''), 2.37 (s, 3H, NCH3). 
1H 
NMR of the minor rotamer (in part):  6.62 (s, 1H, H3'), 3.78 (s, 3H, OCH3-4'), 3.45 
(s, 3H, OCH3-6). 
13C NMR of the major rotamer:  156.0 (q, J 36.9 Hz, COCF3), 
148.5 (C4'), 147.2 (C6), 147.5 (C5'), 147.4 (C7), 131.2 (C2'), 127.5 (C4a), 126.0 
(C1'), 125.1 (C8a), 114.3 (CH-5), 116.9 (q, J 287.5 Hz, COCF3), 112.9 (CH-3'), 
111.2 (CH-6'), 110.9 (CH-8), 56.2 (OCH3-7), 556.1 (OCH3-5'), 56.1 (OCH3-4'), 55.9 
(CH-1), 55.8 (OCH3-6), 53.1 (CH2-2''), 40.9 (CH2-3), 38.2 (CH2-7'), 36.3 (NCH3), 
32.4 (CH2-1''), 28.7 (CH2-4). MS (ESI
+): m/z 497.1 (MH+, 100%). HRMS (ESI+): 
calcd for C25H32F3N2O5, 497.2263 (MH
+), found 497.2237. 
 
(RS)  2-Trifluoroacetyl-1,2,3,4-tetrahydro-1[4'5'-dimethoxy-2'-(N-(2-
chloromethylcarbonyl)-N-methyl-aminomethyl)phenyl]methyl-6,7-
dimethoxyisoquinoline  (38).  
 
To a solution of  36 (99 mg, 0.206 mmol) in dry CH2Cl2 (5 mL) was added 
triethylamine (42 mg, 0.412 mmol, 0.06 mL) at 0 oC followed by chloroacetyl 
chloride (30 mg, 0.268 mmol, 0.02 mL). The reaction was brought to RT and was 
stirred for 18 h. The CH2Cl2 layer was diluted and extracted with 10% aqueous 
NaOH, washed with H2O (2x) and brine. The CH2Cl2 layer was dried (K2CO3) and 
evaporated to give an oil. The oil was purified by column chromatography (EtOAc) to 
give 38 (92 mg, 80% yield) as a clear oil. Compound 38 was a 95:5 mixture of 
rotamers. Rf. 0.67 (EtOAc). 
1H NMR of the major rotamer:  6.63 (s, 2H, H3’, H6’), 
6.58 (s, 1H, H5), 6.25 (s, 1H, H8), 5.45 (t, J 7.3 Hz, H1), 4.48 (d, 1H, J 14.7 Hz, 
H1''), 4.26 (d, 1H, J 14.7 Hz, H1''), 4.01 (ABq, 2H, 6.6 Hz, 2xH2'''), 3.66 (dd, 1H, J 
4.5, 1.8 Hz, H3), 3.81 (s, 6H, OCH3-7, OCH3-5'), 3.79 (s, 3H, OCH3-4'), 3.78-3.74 
(m, 1H, H3), 3.62 (s, 3H, OCH3-6), 3.18 (dd, 1H, J 13.5, 8.1 Hz, H7'), 2.95 (dd, 1H, J 
13.5, 6.9 Hz, H7'), 2.87-2.83 (m, 2H, 2xH4), 2.83 (s, 3H, NCH3). 
1H NMR of the 
minor rotamer (in part):  6.50 (s, 1H, H5), 6.20 (s, 1H, H8). 13C NMR of the major 
rotamer: (signals for COCF3 and COCF3 were not observed),  166.5 (COCH2Cl), 
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148.7 (C4’), 147.4 (C7), 148.1 (C5’), 147.5 (C6), 128.8 (C2’), 127.4 (C1’), 126.5 
(C4a), 125.1 (C8a), 114.4 (CH-3’), 113.4 (CH-6’), 111.1 (CH-5), 110.9 (CH-8), 56.3 
(OCH3-7), 56.1 (OCH3-5', OCH3-4’), 56.0 (OCH3-6), 55.4 (CH-1), 48.3 (CH2-1''), 
41.9 (CH2-2'''), 40.8 (CH2-3), 37.7 (CH2-7'), 34.6 (NCH3), 28.8 (CH2-4). 
13C NMR of 
the minor rotamer (in part):  114.9 (CH-3), 113.6 (CH-6'), 111.3 (CH-5), 50.6 (CH2-
1''), 42.7 (CH2-2'''), 41.1 (CH2-3), 38.0 (CH2-7'), 28.5 (CH2-4). MS (ESI
+): m/z 581.0 
(M(35Cl)+Na+, 10%), 583.0 (M(37Cl)+Na+, 4%). HRMS (ESI+): calcd for 
C26H30F3N2NaO6
35Cl, 581.1642 (M(35Cl)+Na+), found 581.1641. 
 
 
(RS) 2-Trifluoroacetyl-1,2,3,4-tetrahydro-1[4',5'-dimethoxy-2'-(N-(2-
chloromethyl carbonyl)-N-ethyl-aminomethyl)phenyl]methyl-6,7-
dimethoxyisoquinoline  (39).  
 
To a solution of 38 (73 mg, 0.152 mmol) in dry CH2Cl2 (5 mL) was added 
triethylamine (31 mg, 0.304 mmol, 0.041 mL) at 00C, followed by chloroacetyl 
chloride (22 mg, 0.198 mmol, 0.013 mL). The reaction mixture was brought to rt and 
stirred for 18 h. The mixture was worked up as described above in the synthesis of 38 
to give an oil. The oil was purified by column chromatography (EtOAc) to give 39 
(63 mg, 72%) as a clear oil. Compound 39 was a 95:5 mixture of rotamers. Rf. 0.60 
(EtOAc). 1H NMR of the major rotamer:  6.61 (s, 1H, H3'), 6.58 (s, 1H, H6'), 6.55 
(s, 1H, H5), 6.13 (s, 1H, H8), 5.46 (dd, 1H, J 8.4, 6.3 Hz, H1), 4.01 (s, 2H, 2xH2'''), 
3.90 (dt, 1H, J 5.4, 2.1 Hz, H3), 3.81 (s, 6H, OCH3-7, OCH3-5'), 3.82-3.78 (m, 1H, 
H3), 3.75 (s, 3H, OCH3-4'), 3.57 (s, 3H, OCH3-6), 3.45 (dt, 1H, J 9.6, 3.6 Hz, H2''), 
3.29-3.19 (m, 2H, H2'', H7’), 3.06-2.99 (m, 1H, H7'), 2.97 (s, 3H, NCH3), 2.89-2.84 
(m, 2H, 2xH4), 2.61-2.53 (m, 2H, 2xH1''). 1H NMR of the minor rotamer (in part):  
6.59 (s, 1H, H3'), 6.40 (s, 1H, H5), 5.90 (s, 1H, H8), 5.36 (dd, 1H, J 9.3, 4.8 Hz, H1), 
3.67 (s, 6H, OCH3-7, OCH3-5'), 3.63 (s, 3H, OCH3-4'), 3.50 (s, 3H, OCH3-6). 
13C 
NMR of the major rotamer: (signals for COCF3 and COCF3 were not observed),  
116.1 (COCH2Cl), 148.1 (C4'), 147.9 (C7), 147.4 (C5'), 147.1 (C6), 129.8 (C2'), 
127.6 (C1'), 126.3 (C4a), 124.8 (C8a), 114.0 (CH-3'), 112.8 (CH-6), 110.8 (CH-5), 
110.6 (CH-8), 56.9 (OCH3-7), 56.8 (OCH3-5'), 55.8 (OCH3-4'), 55.7 (OCH3-6), 55.6 
(CH-1), 50.4 (CH2-2'''), 41.3 (CH2-2''), 40.5 (CH2-3), 37.8 (CH2-7'), 36.3 (NCH3), 
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29.7 (CH2-1''), 28.4 (CH2-4). 
13C NMR of the minor rotamer (in part):  129.2 (C2'), 
127.2 (C1'), 125.1 (C8a), 114.4 (CH-3), 112.6 (CH-6'), 110.9 (CH-5). MS (ESI+): m/z 
573.0 (M(35Cl)H+, 100%), 575.0 (M(37Cl)H+, 40%). HRMS (ESI+): calcd for 
C27H33N2O6F3
35Cl, 573.1979 (M(35Cl)H+), found 573.1985. 
 
(RS) 3-(1,2)-Benzena-5-(1,2)-isoquinolinacyclo-1-aza-7-oxo-heptaphane (40). 
 
To a solution of 38 (92 mg, 0.165 mmol) in CH3OH (4 mL) and H2O (1 mL) was 
added K2CO3 (112 mg, 0.825 mmol), and the mixture was stirred at rt for 3 h. The 
CH3OH was gently removed under pressure (without warming the water bath) to give 
an aqueous residue. To the mixture was added CH2Cl2 (10 mL), followed by the 
addition of triethylamine (0.3 mL). The reaction was stirred for 18 h at RT. The 
CH2Cl2 layer was washed with H2O (3 x), brine and then dried (K2CO3).  The solvent 
was removed to give an oil which was purified by column chromatography (EtOAc) 
to give 40 (41 mg, 57% yield) as a yellow oil. Rf. 0.35 (EtOAc). 
1H NMR  6.69 (s, 
1H, H3’), 6.61 (s, 1H, H5), 6.41 (s, 1H, H6'), 5.96 (s, 1H, H8), 4.22 (bs, 1H, H1''), 
3.99 (t, 1H, J 7.0 Hz, H1), 3.88 (s, 3H, OCH3-7), 3.82 (s, 3H, OCH3-5'), 3.79 (s, 3H, 
OCH3-4'), 3.52 (s, 3H, OCH3-6), 3.52 (bs, 6H, OCH3-6, 2xH3'', H1''), 3.38-3.32 (m, 
1H, H7'), 3.09 (s, 3H, NCH3), 2.86 (dt, 1H, J 10.5, 3.6 Hz, H3), 2.77 (dd, 1H, J 14.0, 
3.0 Hz, H7'), 2.56 (ddd, 1H, J 14.0, 10.5, 2.5 Hz, H3), 2.27 (bs, 2H, 2xH4).13C NMR 
 172.1 (CO), 147.6 (C4’), 147.5 (C7), 147.4 (C5', C6), 130.0 (C2'), 129.8 (C1'), 
129.2 (C4a), 129.0 (C8a), 115.0 (CH-8), 112.0 (CH-5), 111.0 (CH-6'), 110.4 (CH-3'), 
64.0 (CH-1), 62.1 (CH2-3''), 56.6 (OCH3-7), 56.1 (OCH3-5', OCH3-4'), 55.8 (OCH3-
6), 54.5 (CH2-1''), 49.7 (CH2-3), 40.7 (CH2-7’), 36.2 (NCH3), 30.0 (CH2-4). MS 
(ESI+): m/z 427.1 (MH+, 100%). HRMS (ESI+): calcd for C24H31N2O5, 427.2233 
(MH+), found 427.2227. 
 
(RS) 4-(1,2)-Benzena-6-(1,2)-isoquinolinacyclo-1-aza-8-oxo-octaphane (41). 
 
The synthesis of the tittle compound 41 was carried out using the conditions described 
above for the synthesis of 40 starting with compound 39 (63 mg, 0.108 mmol), 
CH3OH (3 mL), H2O (1 mL) and K2CO3 (112 mg, 0.825 mmol). This was followed 
by intramolecular cyclisation using CH2Cl2 (10 mL) and triethylamine (0.3 mL) to 
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give an oil which was purified by column chromatography (EtOAc) to give 41 (31 
mg, 46% yield) as a yellow oil. Rf. 0.48 (EtOAc). 
1H NMR:  6.71 (s, 1H, H3'), 6.60 
(s, 1H, H6'), 6.53 (s, 1H, H5), 6.36 (s, 1H, H8), 4.06-4.01 (m, 1H, H1), 3.90 (s, 3H, 
OCH3-7), 3.86 (s, 3H, OCH3-5'), 3.85 (s, 3H, OCH3-4'), 3.70 (s, 3H, OCH3-6), 3.47 
(bs, 2H, 2xH4''), 3.29- 3.27 (m, 1H, H7'), 3.12-3.08 (m, 2H, 2xH2''), 3.05 (s, 3H, 
NCH3), 3.00-2.93 (m, 1H, H3), 2.89-2.81 (m, 1H, H7'), 2.77-2.64 (m, 3H, 2xH1'', 
H3), 2.22-2.16 (m, 2H, 2xH4). 13C NMR:  171.4 (CO), 148.5 (C4'), 147.9 (C7), 
147.5 (C5'), 147.1 (C6), 131.7 (C2’), 131.6 (C1'), 128.6 (C4a), 127.9 (C8a), 114.7 
(CH-8), 113.4 (CH-6'), 111.4 (CH-5), 110.6 (CH-3'), 65.1 (CH-1), 60.8 (CH2-4''), 
56.4 (OCH3-7), 56.3 (OCH3-5'), 56.2 (OCH3-4'), 56.1 (OCH3-6), 53.0 (CH2-2''), 52.7 
(CH2-3, CH2-7'), 35.3 (NCH3), 33.8 (CH2-1'', CH2-4). MS (ESI
+): m/z 441.1 (MH+, 
100%). HRMS (ESI+): calcd for C25H33N2O5, 441.2389 (MH
+), found 441.2380. 
 
(RS)-3-(1,2)-Benzena-5-(1,2)-isoquinolinacyclo-1-aza-heptaphane (42). 
 
To a slurry of LiAlH4 (38 mg, 1.02 mmol) in dry THF (1 mL) was added a solution of 
the amide 41 (21 mg, 0.048 mmol) in dry THF (1 mL) under a N2 atmosphere at 0
0C. 
The resulting mixture as brought to rt and stirred for 18 h. H2O (0.2 mL), 1M aqueous 
NaOH (0.2 mL), H2O (0.5 mL) were added subsquently and the reaction was stirred 
for 1 h. The solid was filtered and washed with EtOAc. The solution was dried 
(K2CO3) and evaporated to give 42 (16 mg, 81%) as a clear oil without the need for 
further purification. Rf. 0.15 (CH3OH/EtOAc/NH3 (5:5:0.1)). 
1H NMR  6.84 (s, 1H, 
H3'), 6.64 (s, 1H, H6'), 6.58 (s, 2H, H5, H8), 4.50 (d, 1H, J 12.5 Hz, H1''), 4.22 (bs, 
1H, H1), 3.89 (s, 3H, OCH3-7), 3.86 (s, 6H, OCH3-5', OCH3-4'), 3.83 (s, 3H, OCH3-
6), 3.42 (d, 1H, J 12.5 Hz, H1''), 3.40 (dd, 1H, J 14.0, 7.0 Hz, H7'), 3.15-3.09 (m, 2H, 
2xH3''), 2.81-2.72 (m, 3H, H3, 2xH2''), 2.68 (dd, 1H, J 14.0, 2.0 Hz, H7'), 2.59-2.51 
(m, 3H, H3, 2xH4), 2.52 (s, 3H, NCH3). 
13C NMR  147.6 (C4'), 147.4 (C7), 147.3 
(C5'), 147.1 (C6), 134.0 (C2'), 132.2 (C1'), 131.5 (C4a), 127.5 (C8a), 114.4 (CH-3'), 
113.8 (CH-6), 111.2 (CH-5), 110.7 (CH-8), 61.5 (CH-1), 58.1 (CH2-1''), 56.2 (OCH3-
7), 56.0 (OCH3-5'), 56.0 (OCH3-4'), 55.8 (OCH3-6), 52.0 (CH2-2''), 51.9 (CH2-3), 48.0 
(CH2-7'), 42.6 (NCH3), 29.7 (CH2-3''), 27.1 (CH2-4). MS (ESI
+): m/z 413.2 (MH+, 
100%).  
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